
{
  "Company Overview": {
    "Name": "Source Natural Foods & Herbal Supplements Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs & Formln",
    "Business Description": "Incorporated in 1998, Source Natural Foods and Herbal Supplements Ltd provides Ayurveda, Health & Dietary Supplements and Food Products.  Products include Beverages (Ojasvita - Chocolate, Malt, Strawberry, Mango, Golden Latte, etc.), Supplements (Turmeric Plus, Amla, Yastimadhu, Triphala, Nishamlaki, Arjuna), Arkas (Shakti Drops, Tulsi Araka, Ajamoda Arka), Single Herbs (Shakhpushpi, Shatavari, Tulsi, Neem, Brahmi, Ashwagandha, Amrut, Kalamegh, Haritaki), and Churnas (Sitophaladi, Hingvastaka, Triphala).",
    "Market Position": "Information not explicitly provided, but peer comparison data suggests a smaller market cap compared to competitors."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 135 Cr.",
    "Current Price": "₹ 210",
    "High/Low": "₹ 270 / ₹ 78.0",
    "Stock P/E": "53.0",
    "Book Value": "₹ 32.2",
    "Dividend Yield": "0.00 %",
    "ROCE": "18.5 %",
    "ROE": "9.52 %",
    "Face Value": "₹ 10.0",
    "Debt-to-Equity Ratio": "Information not explicitly provided." 
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": {
        "Sep 2021": "4.25",
        "Dec 2021": "3.91",
        "Mar 2022": "5.48",
        "Jun 2022": "4.37",
        "Sep 2022": "3.40",
        "Dec 2022": "5.17",
        "Mar 2023": "6.83",
        "Jun 2023": "5.58",
        "Sep 2023": "6.89",
        "Dec 2023": "8.00",
        "Mar 2024": "6.83",
        "Jun 2024": "8.16",
        "Sep 2024": "10.26"
      },
      "Expenses": {
        "Sep 2021": "3.82",
        "Dec 2021": "3.72",
        "Mar 2022": "3.97",
        "Jun 2022": "3.57",
        "Sep 2022": "2.89",
        "Dec 2022": "4.68",
        "Mar 2023": "5.07",
        "Jun 2023": "5.09",
        "Sep 2023": "6.16",
        "Dec 2023": "6.25",
        "Mar 2024": "5.35",
        "Jun 2024": "7.27",
        "Sep 2024": "8.89"
      },
      "Net Profit": {
        "Sep 2021": "0.22",
        "Dec 2021": "0.14",
        "Mar 2022": "1.32",
        "Jun 2022": "0.47",
        "Sep 2022": "0.29",
        "Dec 2022": "0.25",
        "Mar 2023": "1.25",
        "Jun 2023": "0.27",
        "Sep 2023": "0.19",
        "Dec 2023": "0.96",
        "Mar 2024": "0.32",
        "Jun 2024": "0.42",
        "Sep 2024": "0.84"
      }
    },
    "Annual Results (P&L)": {
      "Sales": {
        "Mar 2013": "3.76",
        "Mar 2014": "4.54",
        "Mar 2015": "6.54",
        "Mar 2016": "10.93",
        "Mar 2017": "15.94",
        "Mar 2018": "10.84",
        "Mar 2019": "12.81",
        "Mar 2020": "13.59",
        "Mar 2021": "24.88",
        "Mar 2022": "21.53",
        "Mar 2023": "19.79",
        "Mar 2024": "27.30"
      },
      "Net Profit": {
        "Mar 2013": "0.35",
        "Mar 2014": "0.17",
        "Mar 2015": "0.16",
        "Mar 2016": "0.43",
        "Mar 2017": "1.40",
        "Mar 2018": "0.80",
        "Mar 2019": "1.03",
        "Mar 2020": "1.64",
        "Mar 2021": "3.37",
        "Mar 2022": "2.43",
        "Mar 2023": "2.12",
        "Mar 2024": "1.74"
      }
    },
    "Balance Sheet Highlights": {
      "Equity Capital": {
        "Mar 2013": "4.50",
        "Mar 2014": "5.20",
        "Mar 2015": "6.10",
        "Mar 2016": "6.44",
        "Mar 2017": "6.44",
        "Mar 2018": "6.44",
        "Mar 2019": "6.44",
        "Mar 2020": "6.44",
        "Mar 2021": "6.44",
        "Mar 2022": "6.44",
        "Mar 2023": "6.44",
        "Mar 2024": "6.44",
        "Sep 2024": "6.44"
      },
      "Total Liabilities": {
        "Mar 2013": "4.96",
        "Mar 2014": "5.50",
        "Mar 2015": "6.00",
        "Mar 2016": "6.62",
        "Mar 2017": "11.51",
        "Mar 2018": "11.10",
        "Mar 2019": "10.80",
        "Mar 2020": "13.14",
        "Mar 2021": "17.23",
        "Mar 2022": "19.33",
        "Mar 2023": "21.70",
        "Mar 2024": "23.65",
        "Sep 2024": "31.29"
      }
    },
    "Cash Flow Summaries": {
      "Cash from Operating Activity": {
        "Mar 2013": "0.49",
        "Mar 2014": "0.00",
        "Mar 2015": "0.38",
        "Mar 2016": "0.38",
        "Mar 2017": "-0.69",
        "Mar 2018": "0.11",
        "Mar 2019": "2.64",
        "Mar 2020": "-0.36",
        "Mar 2021": "4.46",
        "Mar 2022": "-0.70",
        "Mar 2023": "2.51",
        "Mar 2024": "2.69"
      },
      "Net Cash Flow": {
        "Mar 2013": "0.38",
        "Mar 2014": "0.00",
        "Mar 2015": "0.08",
        "Mar 2016": "0.23",
        "Mar 2017": "-0.58",
        "Mar 2018": "-0.18",
        "Mar 2019": "0.74",
        "Mar 2020": "-0.74",
        "Mar 2021": "2.69",
        "Mar 2022": "-1.83",
        "Mar 2023": "2.04",
        "Mar 2024": "2.95"
      }
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth (10 Years)": "20%",
      "Compounded Sales Growth (5 Years)": "16%",
      "Compounded Sales Growth (3 Years)": "3%",
      "Compounded Sales Growth (TTM)": "36%",
      "Compounded Profit Growth (10 Years)": "26%",
      "Compounded Profit Growth (5 Years)": "11%",
      "Compounded Profit Growth (3 Years)": "-19%",
      "Compounded Profit Growth (TTM)": "30%",
      "Stock Price CAGR (10 Years)": "31%",
      "Stock Price CAGR (5 Years)": "29%",
      "Stock Price CAGR (3 Years)": "20%",
      "Stock Price CAGR (1 Year)": "115%"
    },
    "Liquidity Ratios": {
      "Debtor Days": {
        "Mar 2013": "11.65",
        "Mar 2014": "28.14",
        "Mar 2015": "12.84",
        "Mar 2016": "27.72",
        "Mar 2017": "100.52",
        "Mar 2018": "139.06",
        "Mar 2019": "94.88",
        "Mar 2020": "182.37",
        "Mar 2021": "87.88",
        "Mar 2022": "131.22",
        "Mar 2023": "136.67",
        "Mar 2024": "100.41"
      },
      "Inventory Days": {
        "Mar 2013": "142.99",
        "Mar 2014": "143.08",
        "Mar 2015": "218.30",
        "Mar 2016": "143.24",
        "Mar 2017": "115.92",
        "Mar 2018": "202.88",
        "Mar 2019": "149.49",
        "Mar 2020": "92.38",
        "Mar 2021": "64.09",
        "Mar 2022": "106.83",
        "Mar 2023": "141.55",
        "Mar 2024": "93.53"
      },
      "Days Payable": {
        "Mar 2013": "101.60",
        "Mar 2014": "90.52",
        "Mar 2015": "108.28",
        "Mar 2016": "81.70",
        "Mar 2017": "84.18",
        "Mar 2018": "36.13",
        "Mar 2019": "46.29",
        "Mar 2020": "58.58",
        "Mar 2021": "22.10",
        "Mar 2022": "57.67",
        "Mar 2023": "78.93",
        "Mar 2024": "60.91"
      },
      "Cash Conversion Cycle": {
        "Mar 2013": "53.04",
        "Mar 2014": "80.70",
        "Mar 2015": "122.86",
        "Mar 2016": "89.26",
        "Mar 2017": "132.26",
        "Mar 2018": "305.81",
        "Mar 2019": "198.08",
        "Mar 2020": "216.16",
        "Mar 2021": "129.86",
        "Mar 2022": "180.37",
        "Mar 2023": "199.29",
        "Mar 2024": "133.04"
      },
      "Working Capital Days": {
        "Mar 2013": "46.60",
        "Mar 2014": "58.69",
        "Mar 2015": "58.60",
        "Mar 2016": "53.76",
        "Mar 2017": "111.74",
        "Mar 2018": "178.80",
        "Mar 2019": "114.54",
        "Mar 2020": "183.17",
        "Mar 2021": "82.01",
        "Mar 2022": "163.43",
        "Mar 2023": "157.14",
        "Mar 2024": "114.71"
      }
    },
    "Profitability Ratios": {
      "ROCE %": {
        "Mar 2013": "8.28%",
        "Mar 2014": "3.51%",
        "Mar 2015": "3.31%",
        "Mar 2016": "8.83%",
        "Mar 2017": "20.39%",
        "Mar 2018": "11.62%",
        "Mar 2019": "13.51%",
        "Mar 2020": "20.84%",
        "Mar 2021": "33.11%",
        "Mar 2022": "26.36%",
        "Mar 2023": "17.97%",
        "Mar 2024": "18.49%"
      },
      "ROE": {
        "10 Years": "15%",
        "5 Years": "16%",
        "3 Years": "13%",
        "Last Year": "10%"
      },
      "OPM %": {
        "Sep 2021": "10.12%",
        "Dec 2021": "4.86%",
        "Mar 2022": "27.55%",
        "Jun 2022": "18.31%",
        "Sep 2022": "15.00%",
        "Dec 2022": "9.48%",
        "Mar 2023": "25.77%",
        "Jun 2023": "8.78%",
        "Sep 2023": "10.60%",
        "Dec 2023": "21.88%",
        "Mar 2024": "21.67%",
        "Jun 2024": "10.91%",
        "Sep 2024": "13.35%"
      }
    },
    "Valuation Ratios": {
      "Price to Book": "Information not explicitly provided in a ratio table format, but individual values for Current Price and Book Value are available."
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Sun Pharma.Inds.", "CMP": "1808.85", "P/E": "38.73", "Mar Cap": "434003.71", "Div Yld": "0.75", "NP Qtr": "3037.33", "Qtr Profit Var": "27.86", "Sales Qtr": "13291.39", "Qtr Sales Var": "9.01", "ROCE": "17.32"},
      {"Name": "Cipla", "CMP": "1472.05", "P/E": "25.81", "Mar Cap": "118884.82", "Div Yld": "0.88", "NP Qtr": "1305.01", "Qtr Profit Var": "15.18", "Sales Qtr": "7051.02", "Qtr Sales Var": "5.58", "ROCE": "22.80"},
      {"Name": "Mankind Pharma", "CMP": "2805.20", "P/E": "56.07", "Mar Cap": "112393.74", "Div Yld": "0.00", "NP Qtr": "634.43", "Qtr Profit Var": "34.84", "Sales Qtr": "2529.74", "Qtr Sales Var": "11.91", "ROCE": "24.57"},
      {"Name": "Dr Reddy's Labs", "CMP": "1343.65", "P/E": "21.00", "Mar Cap": "112115.62", "Div Yld": "0.60", "NP Qtr": "1341.90", "Qtr Profit Var": "-15.28", "Sales Qtr": "8038.20", "Qtr Sales Var": "16.45", "ROCE": "26.53"},
      {"Name": "Lupin", "CMP": "2150.70", "P/E": "37.36", "Mar Cap": "98114.41", "Div Yld": "0.37", "NP Qtr": "859.48", "Qtr Profit Var": "74.12", "Sales Qtr": "5672.73", "Qtr Sales Var": "12.59", "ROCE": "15.72"},
      {"Name": "Zydus Lifesci.", "CMP": "973.50", "P/E": "22.90", "Mar Cap": "97956.88", "Div Yld": "0.31", "NP Qtr": "920.20", "Qtr Profit Var": "13.62", "Sales Qtr": "5237.00", "Qtr Sales Var": "19.87", "ROCE": "22.34"},
      {"Name": "Aurobindo Pharma", "CMP": "1241.70", "P/E": "19.96", "Mar Cap": "72756.00", "Div Yld": "0.36", "NP Qtr": "816.95", "Qtr Profit Var": "8.65", "Sales Qtr": "7796.07", "Qtr Sales Var": "7.99", "ROCE": "14.10"},
      {"Name": "Source Natural", "CMP": "210.00", "P/E": "53.01", "Mar Cap": "135.18", "Div Yld": "0.00", "NP Qtr": "0.84", "Qtr Profit Var": "342.11", "Sales Qtr": "10.26", "Qtr Sales Var": "48.91", "ROCE": "18.49"}
    ],
    "Median": {
      "CMP": "512.7",
      "P/E": "33.34",
      "Mar Cap": "2869.55",
      "Div Yld": "0.05",
      "NP Qtr": "17.27",
      "Qtr Profit Var": "19.36",
      "Sales Qtr": "188.19",
      "Qtr Sales Var": "9.43",
      "ROCE": "14.1"
    }
  },
  "Other Insights": {
    "Pros": [
      "Company is expected to give good quarter",
      "Company's working capital requirements have reduced from 145 days to 115 days"
    ],
    "Cons": [
      "Though the company is reporting repeated profits, it is not paying out dividend",
      "Company has a low return on equity of 12.7% over last 3 years.",
      "Company might be capitalizing the interest cost"
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis."
  },
  "Shareholding Pattern": {
    "Promoters": "74.37%",
    "Public": "25.63%",
    "No. of Shareholders": {
      "Dec 2021": "3,189",
      "Mar 2022": "3,249",
      "Jun 2022": "3,276",
      "Sep 2022": "3,125",
      "Dec 2022": "3,120",
      "Mar 2023": "3,115",
      "Jun 2023": "3,127",
      "Sep 2023": "3,241",
      "Dec 2023": "3,271",
      "Mar 2024": "3,387",
      "Jun 2024": "3,966",
      "Sep 2024": "3,834"
    }
  },
  "Documents": {
    "Announcements": [
      "Announcement under Regulation 30 (LODR)-Newspaper Publication  14 Nov - Newspaper publication of unaudited financial results for the quarter and half year ended September 30, 2024.",
      "Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024.  12 Nov",
      "Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024  12 Nov - Board meeting outcome and unaudited financial results for Q2 2024.",
      "Board Meeting Intimation for Consideration Of Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September 2024.  7 Nov - Board meeting to discuss business diversification and financial results.",
      "Announcement Under Regulation 30 - Reconstitution Of Committees  28 Oct - Reconstitution of Board Committees effective October 1, 2024."
    ],
    "Annual Reports": [
      "Financial Year 2024",
      "Financial Year 2023",
      "Financial Year 2022",
      "Financial Year 2021",
      "Financial Year 2020",
      "Financial Year 2019",
      "Financial Year 2018",
      "Financial Year 2017",
      "Financial Year 2016",
      "Financial Year 2015",
      "Financial Year 2014",
      "Financial Year 2013",
      "Financial Year 2012",
      "Financial Year 2011",
      "Financial Year 2010"
    ]
  }
}
